Antibody–drug conjugates (ADCs) have rapidly emerged as one of the most promising modalities in modern biopharmaceutical development. By combining the precision targeting capabilities of monoclonal antibodies with highly potent therapeutic payloads, ADCs enable drugs to be delivered directly to diseased cells while minimising systemic exposure. Structurally, an ADC consists of three key components: a monoclonal antibody that binds to a specific antigen on target cells, a chemical linker that connects the antibody to the payload, and the payload itself, which delivers the therapeutic effect once the ADC reaches the intended site.
To date, most ADCs have been developed using cytotoxic payloads, enabling the targeted delivery of highly potent cell-killing drugs to tumour cells. This approach has made ADCs one of the most promising therapeutic strategies in oncology, improving treatment precision while reducing the systemic toxicity associated with traditional chemotherapy. As a result, the ADC landscape today remains overwhelmingly oncology-focused, with the majority of approved therapies and late-stage pipelines targeting cancers such as breast cancer, haematological malignancies, and urothelial cancers.
At the same time, the field is entering a new phase of innovation. Researchers are increasingly exploring non-cytotoxic payloads, designed to modulate biological pathways rather than directly destroy cells. Often described as the next frontier in ADC development, these approaches could expand the technology beyond oncology into areas such as autoimmune diseases, inflammatory disorders, metabolic conditions, and infectious diseases, where targeted delivery of therapeutic agents could improve efficacy while minimising off-target effects.
Europe and the United Kingdom are playing an increasingly important role in shaping the global ADC ecosystem. The region is home to a growing network of biotechnology innovators, pharmaceutical companies, specialised technology providers, and contract development and manufacturing organisations (CDMOs) supporting ADC discovery, development, and manufacturing. Expanding clinical pipelines, strategic collaborations, and continued investment in advanced biomanufacturing capabilities are strengthening Europe’s position as a key hub for ADC innovation.
This eBook explores the Antibody-Drug Conjugate Landscape across Europe and the UK, mapping the pipelines, platforms, and partnerships powering the next generation of targeted therapies. By examining both the established oncology-driven market and emerging research directions, the report highlights key trends, innovation ecosystems, and the organisations playing a pivotal role in advancing this rapidly evolving therapeutic field.
Antibody + Linker + Payload
Core ADC Structure
Oncology-Dominated Market
Most ADCs target cancer
